ASX:PYCPYC Therapeutics Stock Price, Forecast & News

PYC Therapeutics Limited provides drug discovery research and development services utilizing Phylomer peptide libraries and proprietary screening capabilities in Australia. The company's Phylomer libraries contain various peptides that represent a source of biologically active drug leads for a range of intracellular and extracellular disease targets. It develops next generation intracellular biological therapeutics, including its own preclinical Myc, STAT 5, and YB1 oncology inhibitor payloads using its proprietary cell penetrating functional penetrating Phylomers. The company has approximately 12 patent families comprising multiple granted/allowed patents in the United States and Australia, which cover methods of making the Phylomer libraries; methods of screening them and composition-of-matter claims for Phylomer libraries; and individual Phylomer peptides discovered for therapeutic and diagnostic applications. It has a research and development collaboration with Ramot. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.